Format

Send to

Choose Destination
Thromb Res. 2014 Jul;134(1):11-6. doi: 10.1016/j.thromres.2014.02.028. Epub 2014 Mar 5.

Are the antiplatelet and profibrinolytic properties of selective serotonin-reuptake inhibitors relevant to their brain effects?

Author information

1
Department of Hematology, Hospital Federal dos Servidores do Estado, Ministry of Health, Rio de Janeiro, Brazil.
2
Institute of Psychiatry, Federal University of Rio de Janeiro, National Institute for Translational Medicine (INCT-TM), Brazil.
3
Department of Hematology, University Hospital, Nîmes, France.
4
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus and Technion, Israel Institute of Technology, Haifa, Israel. Electronic address: b_brenner@rambam.health.gov.il.

Abstract

The serotonin transporter (SERT) is found in neuron and platelet membranes. Selective serotonin-reuptake inhibitors (SSRIs) are widely prescribed for severe depression. They may at least partly counteract the effects of serotonin on the vascular biology system, can lower agonists-induced platelet activation, aggregation and procoagulant activity in vitro, thus modulating platelet thrombogenicity. Other effects, such as those mediated through PAI-1 modulation, may indirectly influence neurobiology-relevant mechanisms involved in depression. Patients receiving SSRIs are at increased bleeding risk and decreased risk of arterial occlusive events, such as myocardial infarction, compared to those using non-SSRI antidepressants. The objectives of this review were to highlight antiplatelet and profibrinolytic properties of SSRIs and discuss the potential role of these activities in the context of SSRI brain effects.

KEYWORDS:

Antithrombotics; Selective serotonin-reuptake inhibitors (SSRIs); Severe depression

PMID:
24661990
DOI:
10.1016/j.thromres.2014.02.028
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center